AI Portfolio Summary
In 2025 Q4, Lynx1 Capital Management LP maintained a portfolio of 27 distinct positions. The most significant new addition to the portfolio was XENCOR INC, which now represents 2.19% of the total fund value. They heavily accumulated shares in GH RESEARCH PLC, increasing their position by 21.0%. Conversely, Lynx1 Capital Management LP completely exited their position in ALLOGENE THERAPEUTIC.
Total Positions
27
Quarter
2025 Q4
Top Holding
STOK (34.7%)
Top 10 Concentration
97.2%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-27 of 27
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
STOK
STOKE THERAPEUT...
|
Healthcare | 34.73% | 22.37% |
#1
1
Prev: #2
|
7.0 | no change | no change |
P
S
|
5,404,674 | $171,544,353 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GHRS
GH RESEARCH PLC
|
Healthcare | 26.75% | 21.23% |
#2
1
Prev: #3
|
8.0 | 1,805,386 | 21.0% |
P
S
|
10,406,575 | $132,163,502 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CGEM
CULLINAN THERAP...
|
Healthcare | 18.78% | 6.96% |
#3
2
Prev: #5
|
8.0 | 3,197,410 | 55.5% |
P
S
|
8,963,500 | $92,772,225 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DNLI
DENALI THERAPEU...
|
Healthcare | 5.81% | 0.77% |
#4
7
Prev: #11
|
5.8 | 1,477,063 | 564.4% |
P
S
|
1,738,750 | $28,706,762 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CCCC
C4 THERAPEUTICS...
|
Healthcare | 2.74% | 3.21% |
#5
1
Prev: #6
|
2.6 | no change | no change |
P
S
|
7,098,133 | $13,557,434 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XNCR
XENCOR INC
|
Healthcare | 2.19% | — |
#6
Prev: #—
|
4.4 | 705,558 | no change |
NEW
|
705,558 | $10,802,093 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMTX
IMMATICS N.V
|
Healthcare | 1.96% | — |
#7
Prev: #—
|
4.3 | 921,950 | no change |
NEW
|
921,950 | $9,680,475 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TCRX
TSCAN THERAPEUT...
|
Healthcare | 1.62% | 2.91% |
#8
1
Prev: #7
|
1.1 | 161,801 | 2.1% |
P
S
|
8,019,148 | $8,019,148 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PASG
PASSAGE BIO INC
|
Healthcare | 1.49% | 1.02% |
#9
1
Prev: #10
|
1.6 | no change | no change |
P
S
|
623,704 | $7,359,707 | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KRRO
KORRO BIO INC
|
Healthcare | 1.10% | — |
#10
Prev: #—
|
3.9 | 677,915 | no change |
NEW
|
677,915 | $5,430,099 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DTIL
PRECISION BIOSC...
|
Healthcare | 0.84% | 1.17% |
#11
3
Prev: #8
|
0.8 | -48,683 | -4.7% |
P
S
|
993,913 | $4,134,678 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NEUP
NEUPHORIA THERA...
|
Healthcare | 0.69% | — |
#12
Prev: #—
|
3.8 | 875,228 | no change |
NEW
|
875,228 | $3,395,885 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AGIO
AGIOS PHARMACEU...
|
Healthcare | 0.44% | — |
#13
Prev: #—
|
3.7 | 79,624 | no change |
NEW
|
79,624 | $2,167,365 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CGON
CG ONCOLOGY INC
|
Healthcare | 0.27% | — |
#14
Prev: #—
|
3.6 | 31,591 | no change |
NEW
|
31,591 | $1,311,658 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ARWR
ARROWHEAD PHARM...
|
Healthcare | 0.16% | — |
#15
Prev: #—
|
3.6 | 12,043 | no change |
NEW
|
12,043 | $799,535 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DSGN
DESIGN THERAPEU...
|
Healthcare | 0.13% | 0.10% |
#16
2
Prev: #14
|
2.1 | 3,562 | 5.4% |
P
S
|
69,516 | $652,060 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TRDA
ENTRADA THERAPE...
|
Healthcare | 0.11% | — |
#17
Prev: #—
|
3.5 | 51,689 | no change |
NEW
|
51,689 | $531,363 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
HOWL
WEREWOLF THERAP...
|
Healthcare | 0.08% | — |
#18
Prev: #—
|
3.5 | 655,926 | no change |
NEW
|
655,926 | $415,529 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MPLT
MAPLIGHT THERAP...
|
Healthcare | 0.05% | — |
#19
Prev: #—
|
3.5 | 13,477 | no change |
NEW
|
13,477 | $236,724 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
GENERATION BIO ...
|
—
|
Unknown | 0.03% | — |
#20
Prev: #—
|
3.5 | 25,000 | no change |
NEW
|
25,000 | $142,000 | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
PRQR
PROQR THRAPEUTI...
|
Healthcare | 0.03% | — |
#21
Prev: #—
|
3.5 | 68,486 | no change |
NEW
|
68,486 | $138,342 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
APLT
APPLIED THERAPE...
|
Healthcare | 0.01% | — |
#22
Prev: #—
|
3.5 | 410,500 | no change |
NEW
|
410,500 | $41,050 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALLO
ALLOGENE THERAP...
|
Healthcare | 0.00% | 0.14% |
Sold All 😨
(Was: #13) |
0.0 | -546,119 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IBIO
IBIO INC
|
Healthcare | 0.00% | 0.18% |
Sold All 😨
(Was: #12) |
0.0 | -1,055,897 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ADCT
ADC THERAPEUTIC...
|
Healthcare | 0.00% | 1.08% |
Sold All 😨
(Was: #9) |
0.0 | -1,325,848 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PTGX
PROTAGONIST THE...
|
Healthcare | 0.00% | 9.47% |
Sold All 😨
(Was: #4) |
0.0 | -700,014 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MRUS
MERUS N V
|
Healthcare | 0.00% | 29.40% |
Sold All 😨
(Was: #1) |
0.0 | -1,534,141 | -100.0% |
CLOSED
|
— | $— | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-27 of 27 holdings